Polyneuron Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Liquidation

Polyneuron Pharmaceuticals General Information

Description

Developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Polyneuron Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Bankruptcy: Liquidation 000.00 Completed Bankruptcy: Liquidation
10. Grant 14-Apr-2021 00.000 000.00 Completed Generating Revenue
9. Later Stage VC (Series A) 28-Aug-2020 000.00 000.00 Completed Pre-Clinical Trials
8. Seed Round 14-May-2018 00.000 00.000 00.000 Completed Pre-Clinical Trials
7. Accelerator/Incubator 18-Sep-2017 000.00 00.000 Completed Pre-Clinical Trials
6. Grant 31-Aug-2017 00000 00.000 Completed Pre-Clinical Trials
5. Seed Round 12-May-2016 00.00 00.000 Completed Pre-Clinical Trials
4. Grant 05-May-2016 00000 00000 Completed Pre-Clinical Trials
3. Accelerator/Incubator 15-Jul-2015 $3.35K $150K Completed Startup
2. Accelerator/Incubator 02-Jun-2015 $150K $150K Completed Pre-Clinical Trials
To view Polyneuron Pharmaceuticals’s complete valuation and funding history, request access »

Polyneuron Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series Seed 000,000 000.00 000.00 00 000.00 00.000
To view Polyneuron Pharmaceuticals’s complete cap table history, request access »

Polyneuron Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The compa
Drug Discovery
Basel, Switzerland
9 As of 2022
000.00
00000000000 000.00

000000

a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000 000000000
Hannover, Germany
00 As of 0000
00000
00000000000 00000

000000

m ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incid
0000 000000000
Schlieren, Switzerland
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Polyneuron Pharmaceuticals Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cardior Venture Capital-Backed Hannover, Germany 00 00000 00000000000 00000
ImmunOs Therapeutics Venture Capital-Backed Schlieren, Switzerland 00 0000 00000000000 0000
Marengo Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
SiteOne Therapeutics Venture Capital-Backed San Francisco, CA 000.00 0000000000 000.00
NeRRe Therapeutics Venture Capital-Backed Stevenage, United Kingdom 00 000.00 00000000000 000.00
You’re viewing 5 of 40 competitors. Get the full list »

Polyneuron Pharmaceuticals Patents

Polyneuron Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3056206-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017 000000000
US-20200079808-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017 0000000000
AU-2018235063-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017 000000000
EP-3595730-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017 C07H15/12

Polyneuron Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »